Pharma stock soars 150% on injectables deal with Wegovy maker Novo
Shares in Swedish microcap stock Nanexa more than doubled after the drug-delivery group revealed a licensing deal with European pharma giant Novo Nordisk.


Glideslope AI-powered market news
No market stories in the last 7 days. The latest coverage is below.

No scored stories in the last 7 days.
| Day | Mood | Stories |
|---|---|---|
| Sat, Oct 10 | — | 0 |
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | — | 0 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
| Sat, Oct 3 | — | 0 |
Shares in Swedish microcap stock Nanexa more than doubled after the drug-delivery group revealed a licensing deal with European pharma giant Novo Nordisk.

Novo Nordisk is facing "unprecedented" price pressures, "intensifying competition" and patents expiring.

Novo Nordisk said the job cuts will eliminate about 11% of its workforce, with 5,000 of the reductions in Denmark.
The Danish weight loss drug-maker claims "knock-off" treatments are hitting growth.

The Danish pharmaceutical giant said Fruergaard Jørgensen would remain in his post "for a period to support a smooth transition to new leadership."

Health and wellness company, which sold alternatives to weight-loss drugs like Wegovy, is now collaborating with Wegovy-maker Novo Nordisk.
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE